In short
Clinical trials investigating XELAFASLATIDE are studying whether it can slow disease progression in people with atrophic age-related macular degeneration. These studies mainly look at safety and efficacy, especially in patients with geographic atrophy. The trial data here focuses on a Phase 2 study comparing treatment with a sham injection.
Key points
- XELAFASLATIDE is being studied in a Phase 2 clinical trial for people with atrophic age-related macular degeneration, especially those with geographic atrophy. The study compares the treatment with a sham injection. Researchers want to see if the study treatment can slow disease progression. The main measurement is the size of the geographic atrophy lesion area. The trial is authorised and plans to enroll 324 participants.
Trial overview
The available trial data shows one interventional study of XELAFASLATIDE in atrophic age-related macular degeneration (AMD), which is a form of eye disease that can damage central vision.
The study is designed to evaluate whether XELAFASLATIDE can slow the progression of disease in patients with geographic atrophy (GA) associated with AMD.
Who the trial is for
This trial targets people who have atrophic AMD, with the brief summary specifically naming patients with geographic atrophy linked to AMD.
The source data does not list the full inclusion or exclusion rules, so we only know the main condition being studied from the trial record.
What the study is testing
The study compares XELAFASLATIDE with a sham injection, which means a fake procedure used to help show whether the real treatment has an effect.
The intervention is listed as an ophthalmic solution for intravitreal use, which means it is intended for use in the eye.
The trial summary says the goal is to evaluate efficacy, meaning whether the treatment helps slow the disease compared with the sham procedure.
Trial phase and design
This is a Phase 2 trial, which is a study stage that usually looks more closely at whether a treatment may work while continuing to monitor safety.
The study type is interventional, meaning the researchers assign a treatment and compare outcomes between groups.
What researchers are measuring
The main outcome is GA lesion area assessment.
This means the researchers measure the size of the geographic atrophy area in the retina to see whether the disease is progressing more slowly.
Study status and size
The trial status is listed as Authorised.
The planned enrollment is 324 participants, which gives the study a moderate size for a Phase 2 trial.
Only one trial record was provided, so the article is based on that single study of XELAFASLATIDE.